Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 31 Results

Intervention Indication Therapeutic Area Year Actions
Vedolizumab for treating active pouchitis Vedolizumab (Entyvio; LDP-02; MLN0002) Pouchitis Gastroenterology 2022 View  |  Download
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children Ustekinumab (Stelara; CNTO 1275; CNTO-1275) Crohn's disease Gastroenterology , Immunology 2023 View  |  Download
Ustekinumab for Moderately to Severely Active Ulcerative Colitis Ustekinumab (Stelara; CNTO 1275; CNTO-1275) Ulcerative colitis Gastroenterology 2018 View  |  Download
Upadacitinib for ulcerative colitis Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Ulcerative colitis Gastroenterology 2021 View  |  Download
Upadacitinib for moderate to severe active Crohn’s disease Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Crohn's disease Gastroenterology , Immunology 2021 View  |  Download
Tenapanor for Irritable Bowel Syndrome with Constipation Tenapanor (AZD1722; RDX5791; Ibsrela) Irritable bowel syndrome with predominant constipation (IBS-C) Gastroenterology 2018 View  |  Download
Teduglutide for short bowel syndrome in infants Teduglutide Short bowel syndrome Gastroenterology 2022 View  |  Download
Setmelanotide for obesity in Bardet-Biedl syndrome and Alstrom syndrome Setmelanotide (RM-493) Hyperphagia , Obesity Endocrine Nutritional and Metabolic Disorders , Gastroenterology , Genetic Disorders 2021 View  |  Download
Risankizumab for moderate to severe ulcerative colitis Risankizumab (BI 655066; Skyrizi; ABBV 066) Ulcerative colitis Gastroenterology 2022 View  |  Download
Risankizumab for moderate to severe crohn’s disease Risankizumab (BI 655066; Skyrizi; ABBV 066) Crohn's disease Gastroenterology , Immunology 2021 View  |  Download
1 2 3 4
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications